Daniel Wang Email & Phone Number

Shanghai

• Worked as a full-time offshore analyst for a top four U.S. investment bank, supporting China Healthcare Equity Research Team (Ranked top three by Institutional Investor).• Analyzed companies among different sectors (pharmaceuticals, biologics, TCM, distributors and medical devices) through evaluating macro policies, industry fundamentals, competition landscapes, major products, pipelines, annual reports and company disclosures. • Developed and utilized detailed financial models for the valuation of public and pre-IPO companies, using valuation methods including discounted cash flow method, price earnings multiple valuation and Sum-Of-Parts valuation.• Created and updated industry databases including healthcare indices, industry data, tender progress, new drugs approvals, price track of APIs and batch release of biotech products. • Co-wrote 2010 and 2011 China Healthcare Handbook, including in-depth data and analysis on healthcare industry, sub-sectors and hospital drugs sales data, receiving hundreds of client requests from institution investors.• Compiled marketing materials and assisted in the road shows.• Received the top rating among analyst class (top 5% analysts) in 2010 and 2011 annual performance evaluation.• Awarded Employee Performance Reward in 2011.

• Performed on-site statutory and IPO audit engagements for four Chinese, three European and two U.S. clients in manufacturing industry.• Created revenue and profit projection models for IPO audit of China Northern Locomotive and Rolling Stock Industry Corporation. • Prepared and reviewed financial statements, footnote disclosures and auditor’s reports.• Evaluated the design and operating effectiveness of internal control systems.